Intangible Assets, Net (Tables)

6 Months Ended

Jun. 30, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible asset

The gross carrying amounts and net book value of our intangible assets are as follows:

		June 30, 2022
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization		Net Book Value
Barhemsys intangible (1)	9	$	68,000	$	(468)	$	67,532
Byfavo intangible (1)	9	36,000		(230)		35,770
Ryanodex intangible (2)	9	15,000		(6,241)		8,759
Vasopressin milestone (3)	1	750		(337)		413
Total		$	119,750	$	(7,276)	$	112,474

		December 31, 2021
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization		Net Book Value
Ryanodex intangible (1)	9	$	15,000	$	(5,079)	$	9,921
Developed technology	5	8,100		(8,100)		—
Vasopressin milestone (3)	1	750		—		750
Total		$	23,850	$	(13,179)	$	10,671

(1) Represents intangible assets acquired in the Acacia acquisition as detailed in Note 14.

(2) Represents a one-time payment made to reduce the royalties payable to a third party on Ryanodex net sales.

(3) Represents milestone paid to a third party upon FDA approval of vasopressin.

Schedule of future amortization expense of finite-lived intangible assets

Based on definite-lived intangible assets recorded as of June 30, 2022, and assuming that the underlying assets will not be impaired and that we will not change the expected lives of the assets, future amortization expenses are estimated as follows:

	Estimated Amortization Expense
Year Ending December 31,
2022 (remainder)	7,379
2023	14,405
2024	14,127
2025	13,886
2026	11,584
Thereafter	51,093
Total estimated amortization expense	$	112,474